NOT FOR HUMAN CONSUMPTION

Phenylpiracetam: Benefits, Mechanism, Safety & Research Review

Phenylpiracetam, also known as fonturacetam, 4-phenylpiracetam or carphedon, is a synthetic racetam-class nootropic and stimulant-like compound structurally derived from piracetam by addition of a phenyl group. Its molecular formula is C₁₂H₁₄N₂O₂, molecular weight approximately 218.25 g/mol, and CAS number 77472-70-9.

It has historically been used and studied mainly in Russia for conditions involving cognitive impairment, asthenia, stroke rehabilitation, brain injury and neurological dysfunction.

Unlike conventional piracetam, phenylpiracetam appears to have more pronounced effects on arousal, locomotor activity and catecholaminergic signaling, which probably contributes to its stimulant-like reputation.

---

Potential Benefits of Phenylpiracetam

Benefit	Key take-away
1 Cognitive function	Human clinical studies report improvements in selected cognitive measures in neurological populations, although the overall evidence base is geographically concentrated and methodologically variable.
2 Attention & mental performance	Phenylpiracetam appears more stimulating than piracetam and may influence attention, alertness and psychomotor performance.
3 Asthenia / fatigue	A 2025 meta-analysis covering 549 patients found significant improvement in asthenia scores after one month of fonturacetam treatment.
4 Post-stroke rehabilitation	Controlled studies have reported improvements in functional and cognitive recovery after ischemic stroke.
5 Brain injury / encephalopathy	Clinical studies suggest possible improvements in memory, attention, motor function and daily activity following acquired brain injury.
6 Epilepsy adjunct therapy	One randomized placebo-controlled trial reported reduced seizure frequency and improved cognition when phenotropil was added to antiepileptic therapy.
7 Dopaminergic activity	S-phenylpiracetam has demonstrated selective dopamine transporter (DAT) inhibition in experimental research.
8 Physical performance	Stimulant-like and adaptogenic effects have historically been reported, but modern controlled performance data are limited.
9 Healthy cognition	Strong evidence for substantial cognitive enhancement in healthy individuals remains limited.

---

2. Phenylpiracetam Mechanism of Action

2.1 Racetam and Catecholaminergic Activity

Phenylpiracetam’s exact mechanism is not completely established.

Like other racetams, it has been associated with effects on:

• synaptic plasticity

• cognition-related neurotransmission

• neuronal membrane function

• learning and memory pathways

However, phenylpiracetam appears pharmacologically distinct from piracetam because the phenyl substitution increases CNS activity and produces more pronounced psychostimulant-like effects.

---

2.2 Dopamine Transporter Signaling

One particularly important mechanistic finding concerns the dopamine transporter.

Experimental research identified S-phenylpiracetam as a selective dopamine transporter inhibitor, without comparable direct effects on norepinephrine or serotonin transporters in that experimental system.

DAT inhibition can increase extracellular dopamine signaling and may contribute to:

• motivation,

• wakefulness,

• locomotor activity,

• cognitive engagement,

• reduced fatigue.

However, the marketed racemic compound contains both R- and S-enantiomers, and their pharmacological effects differ.

---

3. R-Phenylpiracetam vs S-Phenylpiracetam

Phenylpiracetam is normally a racemic mixture.

Preclinical studies suggest considerable stereoselectivity.

R-Phenylpiracetam

R-phenylpiracetam showed stronger:

• memory-enhancing activity,

• locomotor stimulation,

• antidepressant-like activity

in animal behavioral testing.

Memory enhancement in one passive-avoidance model occurred with R-phenylpiracetam but not S-phenylpiracetam.

S-Phenylpiracetam

S-phenylpiracetam has been characterized particularly for:

• dopamine transporter inhibition

• metabolic effects

• reduced body-weight gain in animal models

S-phenylpiracetam reduced fat accumulation, glucose and leptin levels in obese rodents without increasing locomotor activity in the relevant experiments.

This means the two enantiomers should not automatically be considered pharmacologically interchangeable.

---

4. Proposed Downstream Biology

Pathway	Functional outcome	Evidence
Dopamine transporter inhibition	Dopaminergic signaling ↑	Preclinical
Synaptic plasticity	Learning / memory support	Preclinical + indirect clinical
CNS activation	Alertness / psychomotor activity	Preclinical + clinical observations
Neuroplasticity	Potential neurological recovery	Translational
Metabolic signaling	Reduced weight gain / glucose effects	S-enantiomer, animal data

A simplified model is:

Phenylpiracetam → racetam-like neuroplasticity + catecholaminergic modulation → increased cognitive/psychomotor activation

---

5. Human Clinical Evidence

5.1 Stroke Rehabilitation

One controlled clinical study examined approximately 400 patients with ischemic stroke, half of whom received phenotropil as part of rehabilitation.

Phenylpiracetam was associated with improvements in recovery outcomes during the year following stroke.

Other smaller studies have also evaluated phenylpiracetam following cerebrovascular injury.

---

5.2 Acquired Brain Injury

A comparative study involving 99 patients with neurological deficits following:

• stroke,

• traumatic brain injury,

• brain-tumor surgery

reported improvements in:

• memory,

• attention,

• motor coordination,

• higher cognitive functions,

• daily activity

during phenotropil treatment.

These findings are clinically interesting but do not meet the evidentiary standard of large modern multinational Phase III trials.

---

6. Asthenia and Fatigue

Asthenia is one of the more extensively studied modern indications.

A 2025 systematic review and meta-analysis evaluated 11 studies involving 549 patients treated with fonturacetam.

At a daily dose of 200 mg for approximately one month, mean MFI-20 asthenia scores decreased by approximately:

16.3 points

with additional reported improvements in:

• emotional state,

• cognition,

• sleep,

• quality of life.

The overall adverse-event frequency was approximately 5.5%, with reported effects generally transient.

This represents one of the strongest aggregated clinical datasets currently available for phenylpiracetam.

---

7. Epilepsy Research

A randomized, double-blind, placebo-controlled trial studied phenotropil as adjunctive therapy in 90 adults with focal epilepsy.

Participants received:

• 100 mg,

• 200 mg,

• or placebo.

Phenotropil was reported to reduce seizure frequency and improve cognitive measures in selected patients without epileptiform EEG abnormalities.

This finding is interesting but requires independent replication before phenylpiracetam could be considered an established epilepsy therapy.

---

8. Phenylpiracetam Pharmacokinetics

Publicly accessible high-quality human pharmacokinetic information is relatively limited compared with drugs such as piracetam or oxiracetam.

Phenyl substitution increases lipophilicity relative to piracetam and is generally understood to contribute to:

• stronger CNS penetration,

• greater potency,

• more pronounced stimulant-like effects.

However, widely repeated online figures for:

• exact half-life,

• bioavailability,

• peak concentration,

• elimination time

are not supported by a comparably robust modern human PK literature.

Therefore, precise retail claims about phenylpiracetam pharmacokinetics should be interpreted cautiously.

---

9. Phenylpiracetam Safety and Side Effects

Clinical research generally suggests reasonable short-term tolerability, but the safety database is substantially smaller than for established medicines.

Reported or plausible adverse effects include:

• insomnia,

• increased activation,

• restlessness,

• headache,

• anxiety or irritability,

• cardiovascular stimulation,

• appetite changes.

The 2025 asthenia meta-analysis reported adverse events in approximately 5.5% of treated patients, generally described as transient.

Long-term safety in healthy users remains inadequately characterized.

---

10. Important Safety Limitations

Major evidence gaps include:

• prolonged daily use,

• cardiovascular safety,

• psychiatric effects in susceptible individuals,

• dependence/tolerance potential,

• interactions with stimulants,

• pregnancy and breastfeeding,

• high-dose exposure,

• use in healthy young adults.

Commercial “nootropic” products may also differ substantially in purity from pharmaceutical preparations used in clinical studies.

---

11. Phenylpiracetam vs Piracetam

Feature	Phenylpiracetam	Piracetam
Racetam	Yes	Yes
CNS stimulation	More pronounced	Minimal
Dopaminergic involvement	Greater evidence	Limited
Cognitive clinical studies	Yes	Extensive
Stroke research	Yes	Yes
Asthenia research	Yes	Less specific
Athletic stimulant potential	Higher	Low
WADA prohibited	Yes	No comparable listing
Healthy cognition evidence	Limited	Limited/mixed

---

12. Sports and WADA Status

Phenylpiracetam is particularly important in competitive sport.

The 2026 WADA Prohibited List explicitly lists:

Fonturacetam [4-phenylpiracetam (carphedon)]

under S6.A Non-Specified Stimulants.

It is therefore prohibited in competition.

Phenylpiracetam has historically been associated with doping-control concerns because of its stimulant and physical-performance effects.

---

13. Regulatory and Research Status

• Generic name: Fonturacetam

• Common names: Phenylpiracetam, Phenotropil, Carphedon

• CAS: 77472-70-9

• Formula: C₁₂H₁₄N₂O₂

• Molecular weight: 218.25 g/mol

• Class: Racetam / nootropic / stimulant-like CNS agent

• FDA-approved medicine: No evidence of FDA drug approval

• WADA: Prohibited in competition

FDA’s substance registry recognizes fonturacetam as a defined substance but explicitly notes that a UNII listing does not imply regulatory review or approval.

---

14. Evidence Profile

Claim	Evidence strength
CNS-active racetam	Strong
Greater stimulant activity than piracetam	Moderate–strong
R/S enantiomers differ pharmacologically	Strong preclinical
S-enantiomer inhibits DAT	Strong preclinical
Improves asthenia	Moderate clinical evidence
Benefits post-stroke recovery	Moderate but older/regional evidence
Improves cognition after neurological injury	Moderate
Improves cognition in epilepsy patients	Preliminary RCT evidence
Improves cognition in healthy adults	Weak / insufficient
Improves athletic performance	Plausible but poorly quantified clinically
Long-term safety is established	No

---

15. Future Directions

Future phenylpiracetam research should focus on:

• modern randomized multicenter trials,

• direct R- vs S-enantiomer comparisons,

• full human pharmacokinetic characterization,

• dopamine-transporter occupancy studies,

• cardiovascular safety,

• long-term neuropsychiatric effects,

• stroke and brain-injury rehabilitation,

• objectively measured fatigue and cognitive performance,

• efficacy in healthy versus cognitively impaired populations.

A particularly interesting research direction is separation of R-phenylpiracetam’s cognitive profile from S-phenylpiracetam’s dopaminergic/metabolic activity.

---

16. Overall Evidence Assessment

Phenylpiracetam is a more pharmacologically active and stimulant-like racetam than conventional piracetam.

Its scientific literature includes genuine human clinical studies in:

• asthenia,

• stroke rehabilitation,

• acquired brain injury,

• epilepsy,

• cognitive dysfunction.

A recent 2025 meta-analysis also provides supportive evidence for improvement of asthenia symptoms.

Best-supported findings

• Racetam-class CNS activity

• Greater psychostimulant activity than piracetam

• Distinct pharmacology of R- and S-enantiomers

• Dopamine-transporter activity of S-phenylpiracetam

• Clinical evidence for reduced asthenia

• Some evidence for neurological rehabilitation

• Explicit WADA stimulant classification

Claims with weaker evidence

• Major cognitive enhancement in healthy adults

• Long-term productivity enhancement

• Permanent memory improvement

• Established athletic-performance enhancement

• Long-term safety during chronic use

Overall: Phenylpiracetam (fonturacetam) is a clinically studied, stimulant-like racetam with evidence for anti-asthenic and neurological-rehabilitation effects and notable dopaminergic pharmacology. Its evidence base is stronger than that of many experimental nootropics, but healthy-person cognitive enhancement and long-term safety remain insufficiently established.